INNOVATE Q1 revenue up 33% to $364.8M; net loss narrows to $17.2M; adjusted EBITDA rises 174% to $19.7M

INNOVATE Corp.

2026-Q1 EPS reported -$1.29 revenue$364,800,000

Infrastructure segment revenue $357.9M (+35.1% YoY); DBMG reported backlog $1.6B, adjusted backlog $1.8B.
Life Sciences: MediBeacon received CE mark under EU MDR for Transdermal GFR Monitor and Reusable Sensor.
Spectrum revenue $5.3M (down 14.5% YoY) on advertising softness; collaborative trials underway with major carrier.
Net loss per diluted share improved to ($1.29) from ($1.89) YoY; Total Adjusted EBITDA $19.7M vs $7.2M.
Cash and cash equivalents $134.6M at March 31, 2026; non-operating corporate cash $2.5M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INNOVATE Corp. reported the three months ended March 31, 2026 results: revenue $364.8 million, net income $(17.2) million, EPS $(1.29).

Period: the three months ended March 31, 2026
Revenue: $364.8 million
Net income: $(17.2) million
EPS: $(1.29)
Result: reported results

Exact text from the filing

to gain support, but still waiting for FCC approvals. First Quarter 2026 Financial Highlights • Revenue: For the first quarter of 2026, INNOVATE's consolidated revenue was $364.8 million, an increase of 33.0%, compared to $274.2 million for the prior year quarter. The increase was driven primarily by our Infrastructure segment, which was partially offset by

View on SEC.gov

Browse all earnings releases →

INNOVATE Corp. filing history →

Source: SEC EDGAR

accession 0001006837-26-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.